4BASEBIO UK SOCIETAS (4BB) - Total Assets
Based on the latest financial reports, 4BASEBIO UK SOCIETAS (4BB) holds total assets worth GBX36.87 Million GBX (≈ $4.49K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 4BASEBIO UK SOCIETAS (4BB) balance sheet quality index to measure how much of total assets are equity-financed.
4BASEBIO UK SOCIETAS - Total Assets Trend (2019–2024)
This chart illustrates how 4BASEBIO UK SOCIETAS's total assets have evolved over time, based on quarterly financial data. Check 4BASEBIO UK SOCIETAS (4BB) tangible equity ratio to evaluate the tangible quality of the company's equity base.
4BASEBIO UK SOCIETAS - Asset Composition Analysis
Current Asset Composition (December 2024)
4BASEBIO UK SOCIETAS's total assets of GBX36.87 Million consist of 82.5% current assets and 17.5% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 77.4% |
| Accounts Receivable | GBX283.00K | 0.6% |
| Inventory | GBX374.00K | 0.8% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX3.48 Million | 7.8% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how 4BASEBIO UK SOCIETAS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 4BB market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 4BASEBIO UK SOCIETAS's current assets represent 82.5% of total assets in 2024, an increase from 51.8% in 2019.
- Cash Position: Cash and equivalents constituted 77.4% of total assets in 2024, up from 6.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 38.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 7.8% of total assets.
4BASEBIO UK SOCIETAS Competitors by Total Assets
Key competitors of 4BASEBIO UK SOCIETAS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
4BASEBIO UK SOCIETAS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.36 | 2.73 | 20.05 |
| Quick Ratio | 11.15 | 2.53 | 19.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX26.18 Million | GBX3.12 Million | GBX15.00 Million |
4BASEBIO UK SOCIETAS - Advanced Valuation Insights
This section examines the relationship between 4BASEBIO UK SOCIETAS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.61 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 275.2% |
| Total Assets | GBX44.73 Million |
| Market Capitalization | $989.13K USD |
Valuation Analysis
Below Book Valuation: The market values 4BASEBIO UK SOCIETAS's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: 4BASEBIO UK SOCIETAS's assets grew by 275.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for 4BASEBIO UK SOCIETAS (2019–2024)
The table below shows the annual total assets of 4BASEBIO UK SOCIETAS from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX44.73 Million ≈ $5.44K |
+275.16% |
| 2023-12-31 | GBX11.92 Million ≈ $1.45K |
+1.99% |
| 2022-12-31 | GBX11.69 Million ≈ $1.42K |
-20.49% |
| 2021-12-31 | GBX14.70 Million ≈ $1.79K |
-17.45% |
| 2020-12-31 | GBX17.81 Million ≈ $2.17K |
+1441.90% |
| 2019-12-31 | GBX1.16 Million ≈ $140.53 |
-- |
About 4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5' and 3' ends for viral and non-viral vector applicat… Read more